Press release
Emerging Sub-Segments Transforming the Ischemic Heart Disease (IHD) Drugs Market Landscape
Ischemic Heart Disease (IHD) Drugs
Projected Market Size for Ischemic Heart Disease Drugs by 2030
The market for ischemic heart disease drugs is anticipated to reach a value of $7.99 billion by 2030, growing at a compound annual growth rate (CAGR) of 3.7%. This progression is supported by several factors including breakthroughs in precision medicine, the integration of digital health technologies, a rising preference for combination therapies, novel drug delivery innovations, and the expansion of telehealth and remote patient monitoring services. Key trends that will shape the market involve personalized cardiac treatment approaches, formulation of combination drugs, telemedicine-enabled cardiac care, advanced cardiovascular risk prediction and monitoring tools, and minimally invasive delivery methods.
Download a free sample of the ischemic heart disease (ihd) drugs market sample:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13467&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR
Leading Pharmaceutical Players in the Ischemic Heart Disease Drugs Market
The ischemic heart disease drugs market features a range of prominent pharmaceutical companies. Some of the top players include Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, and Viatris Inc. Additional key participants are Teva Pharmaceutical Industries Ltd., Sandoz Inc., Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Ltd., Cipla Limited, Lupin Limited, Recordati S.p.A., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alembic Pharmaceuticals Ltd., Accord Healthcare Limited, Macleods Pharmaceuticals Ltd., and Novitium Pharma LLC.
Strategic Acquisitions Enhancing Market Presence
In March 2024, Novo Nordisk, a leading pharmaceutical firm based in Denmark, acquired Cardior Pharmaceuticals for an undisclosed sum. This move is part of Novo Nordisk's strategic plan to broaden its cardiovascular disease portfolio, addressing one of the world's most critical health challenges. Cardior Pharmaceuticals, headquartered in Germany, specializes in manufacturing cardiovascular treatments specifically for ischemic heart disease, making this acquisition a valuable addition to Novo Nordisk's offerings.
View the full ischemic heart disease (ihd) drugs market report:
https://www.thebusinessresearchcompany.com/report/ischemic-heart-disease-ihd-drugs-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR
Trends Impacting Growth in the IHD Drugs Market
Pharmaceutical companies in the ischemic heart disease drugs sector are actively pursuing regulatory approvals and expanding drug indications to strengthen available therapeutic options and capture larger market shares. For example, in June 2023, US-based Bristol Myers Squibb announced that the European Commission approved Camzyos (mavacamten), marking it as the first allosteric, selective cardiac myosin inhibitor for symptomatic NYHA class II-III obstructive hypertrophic cardiomyopathy (HCM).
Further, the FDA in the United States approved a supplemental new drug application for Camzyos the same year, based on Phase 3 VALOR HCM clinical trial data. This data demonstrated a significant decrease in the need for septal reduction therapy among treated patients. Such regulatory milestones and expanding labels for myosin inhibitors are pivotal drivers of growth within the IHD drug market.
Comprehensive Segmentation of the Ischemic Heart Disease Drugs Market
This market is systematically categorized by drug class, disease type, and end user. The drug classes include Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasodilators, and Antithrombotic Agents.
In terms of disease classification, the focus lies on Angina Pectoris and Myocardial Infarction. The end-user segments cover Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy channels.
Breakdown of Subcategories Reveals Detailed Market Insights
Each drug class is further divided into specific subcategories. Anti-Dyslipidemic Drugs include Statins, Fibrates, Niacin, and Cholesterol Absorption Inhibitors. Calcium Channel Blockers are segmented into Dihydropyridines and Non-Dihydropyridines. Beta-Blockers comprise Cardioselective Beta-Blockers, Non-Selective Beta-Blockers, and Vasodilating Beta-Blockers.
For Angiotensin-Converting Enzyme (ACE) Inhibitors, key drugs include Enalapril, Lisinopril, and Ramipril. Angiotensin II Receptor Blockers (ARBs) consist of Losartan, Valsartan, and Irbesartan. Vasodilators are represented by Nitroglycerin, Isosorbide Dinitrate, and Hydralazine. Antithrombotic Agents include both Antiplatelet Drugs and Anticoagulants, completing a detailed overview of the IHD drugs market landscape.
Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Emerging Sub-Segments Transforming the Ischemic Heart Disease (IHD) Drugs Market Landscape here
News-ID: 4498266 • Views: …
More Releases from The Business Research Company
Percutaneous Puncture Surgery Robot Market Analysis Highlights Growth To $3.54 B …
The market for percutaneous puncture surgery robots is on the verge of significant expansion, driven by rapid technological advances and increasing adoption in healthcare settings. As robotic systems become more sophisticated and integrated with cutting-edge technologies, this sector is set to transform minimally invasive surgical procedures. Below is a detailed exploration of the market's size, key players, trends, and segmentation that shape its future trajectory.
Projected Growth and Market Size of…
Pedicle Screw Systems Market Study Highlights How Industry Demand Is Evolving
The pedicle screw systems market is set to experience significant expansion in the coming years, driven by advancements in spinal surgery techniques and increasing patient demand. This market's evolution reflects growing medical needs and ongoing innovation, positioning it for substantial growth by 2030.
Forecasted Market Size and Growth Trajectory for Pedicle Screw Systems
The value of the pedicle screw systems market is projected to reach $7.65 billion by 2030, growing…
Pediatric Orthopedic Implants Market Research Reveals Strong 10.8% CAGR Outlook …
The pediatric orthopedic implants market is on track for significant expansion as advancements in technology and growing healthcare needs drive demand. Innovations in implant design and personalized treatment options are setting the stage for transformative growth in this specialized segment of medical devices. Below is a detailed overview of the current market size, key industry players, emerging trends, and segmentation that define this market's future.
Pediatric Orthopedic Implants Market Size and…
Pediatric Interventional Cardiology Market Intelligence Report Covers Trends, Se …
The pediatric interventional cardiology field is on track for significant expansion, driven by advances in medical technology and growing demand for specialized cardiac care for children. This sector is expected to see dynamic growth as innovative devices and techniques become more widely adopted to improve patient outcomes.
Projected Market Size and Growth Trajectory of the Pediatric Interventional Cardiology Market
The market for pediatric interventional cardiology is forecasted to grow steadily,…
More Releases for Pharma
Schizophrenia Market Gains Momentum with Expanding Pipeline and Investment Poten …
The Key Schizophrenia Companies in the market include - Teva Pharmaceutical Industries, Royalty Pharma, MedinCell, Sumitomo Pharma, Otsuka Pharmaceuticals, Reviva Pharmaceuticals, Minerva Neurosciences, Mitsubishi Tanabe Pharma, Lundbeck, Intra-cellular Therapies, Sumitomo Pharma, Otsuka Pharma, Acadia Pharmaceuticals, Boehringer Ingelheim, Cerevel Therapeutics, AstraZeneca, Eli Lilly and Company, Karuna Therapeutics, Neurocrine Biosciences, and others.
DelveInsight's report "Schizophrenia Market Insights, Epidemiology, and Market Forecast-2036" provides a comprehensive analysis of the Schizophrenia landscape. The report delivers detailed…
Schizophrenia Market: Expanding Revenue Landscape to 2034 - DelveInsight | Teva …
The Key Schizophrenia Companies in the market inlclude - Teva Pharmaceutical Industries, Royalty Pharma, MedinCell, Sumitomo Pharma, Otsuka Pharmaceuticals, Reviva Pharmaceuticals, Minerva Neurosciences, Mitsubishi Tanabe Pharma, Lundbeck, Intra-cellular Therapies, Sumitomo Pharma, Otsuka Pharma, Reviva Pharmaceuticals, and others.
DelveInsight's report "Schizophrenia Market Insights, Epidemiology, and Market Forecast-2034" provides a comprehensive analysis of the Schizophrenia landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the…
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031.
The Dacarbazine market is projected to witness significant growth in the coming years, driven by increasing…
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031.
The dacarbazine market is experiencing steady growth, driven by the rising incidence of cancer globally. As…
Epilepsy Pipeline Assessment 2024: Therapies, Clinical Trials, and Market Insigh …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Epilepsy pipeline constitutes 75+ key companies continuously working towards developing 90+ Epilepsy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Epilepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the…
Global Indomethacin Market Seeking Excellent Growth by 2028 | Ratiopharm, Merck, …
"IBI has published a report entitled Global Indomethacin Market Research Report which provides comprehensive data on emerging trends, market drivers, growth opportunities, and barriers that could change the dynamics of the industry market. It provides an in-depth analysis of market segments which includes the product, application, and competitor analysis.
Click Here To Order A Sample Copy Of Indomethacin Global Market Report : https://www.infinitybusinessinsights.com/request_sample.php?id=380382
The Indomethacin Global Market Research Report provides close monitoring…
